Literature DB >> 15454897

Nosocomial Stenotrophomonas maltophilia cross-infection: three cases in newborns.

Hande Gulcan1, Cigdem Kuzucu, Riza Durmaz.   

Abstract

BACKGROUND: Increased nosocomial Stenotrophomonas maltophilia infection rates in newborns, especially in recent years, are a significant cause for concern. These cases are the second case group in the literature to have been identified as nosocomial cross-infection with S. maltophilia in neonates.
OBJECTIVE: To investigate the clinical, microbiological, and epidemiologic features of the outbreak caused by S. maltophilia in the neonatal intensive care unit within a period of 7 days.
METHODS: Three cases with nosocomial S. maltophilia infection considered to be the result of cross-transmission were prospectively analyzed. Arbitrarily primed polymerase chain reaction (AP-PCR) performed with M13 primer and pulsed-field gel electrophoresis (PFGE) of genomic DNA after digestion with XbaI were used to determine clonal relationship among the isolates. Results S. maltophilia was isolated from the blood cultures of all 3 patients. Molecular typing confirmed that the 3 cases were epidemiologically linked.
CONCLUSIONS: Opportunistic pathogens such as S. maltophilia can lead to major problems in neonates. Molecular typing is helpful to improve effective control programs for preventing the spread of the infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454897     DOI: 10.1016/j.ajic.2004.07.003

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  8 in total

1.  Trimethoprim-Sulfamethoxazole for Treatment of Stenotrophomonas maltophilia Pneumonia in a Neonate.

Authors:  Karen Leask Ryan; Deonne Dersch-Mills; Deborah Clark
Journal:  Can J Hosp Pharm       Date:  2013-11

2.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

Review 3.  The versatility and adaptation of bacteria from the genus Stenotrophomonas.

Authors:  Robert P Ryan; Sebastien Monchy; Massimiliano Cardinale; Safiyh Taghavi; Lisa Crossman; Matthew B Avison; Gabriele Berg; Daniel van der Lelie; J Maxwell Dow
Journal:  Nat Rev Microbiol       Date:  2009-07       Impact factor: 60.633

4.  Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors, and outcome.

Authors:  Saad Nseir; Christophe Di Pompeo; Hélène Brisson; Florent Dewavrin; Stéphanie Tissier; Maimouna Diarra; Marie Boulo; Alain Durocher
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 5.  Stenotrophomonas maltophilia as an Emerging Ubiquitous Pathogen: Looking Beyond Contemporary Antibiotic Therapy.

Authors:  Anthony A Adegoke; Thor A Stenström; Anthony I Okoh
Journal:  Front Microbiol       Date:  2017-11-30       Impact factor: 5.640

6.  Prevalence and Antibiotic Resistance of Stenotrophomonas maltophilia in Respiratory Tract Samples: A 10-Year Epidemiological Snapshot.

Authors:  Márió Gajdács; Edit Urbán
Journal:  Health Serv Res Manag Epidemiol       Date:  2019-08-15

7.  Molecular Epidemiology, Antibiotic Resistance, and Virulence Traits of Stenotrophomonas maltophilia Strains Associated With an Outbreak in a Mexican Tertiary Care Hospital.

Authors:  Ariadnna Cruz-Córdova; Jetsi Mancilla-Rojano; Víctor M Luna-Pineda; Gerardo Escalona-Venegas; Vicenta Cázares-Domínguez; Christopher Ormsby; Isabel Franco-Hernández; Sergio Zavala-Vega; Mónica Andrés Hernández; Marisol Medina-Pelcastre; Israel Parra-Ortega; Daniela De la Rosa-Zamboni; Sara A Ochoa; Juan Xicohtencatl-Cortes
Journal:  Front Cell Infect Microbiol       Date:  2020-02-18       Impact factor: 5.293

8.  Risk Factors for Mortality in Hospitalized Patients with Stenotrophomonas maltophilia Bacteremia.

Authors:  Jiyong Jian; Zeqiang Xie; Liang Chen
Journal:  Infect Drug Resist       Date:  2022-07-21       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.